Recent conversations shaping biopharma manufacturing

**Domestic capacity and supply resilience:
** GSK plans to invest more than $800 million in an integrated biopharma manufacturing and innovation hub in Pennsylvania, while UCB has dedicated a site for a planned $2 billion biologics campus in Georgia. Both projects point to continued investment in U.S. production, R&D, and jobs.

**Automation and AI move into facility design:
** UCB says its Georgia campus will use automation, AI, and advanced manufacturing technologies. Industry coverage also highlights AI and analytics as tools for process optimization and more connected CDMO operations.

**Flexible manufacturing is becoming a strategic choice:
** Recent industry discussion frames single-use technologies not just as equipment, but as enablers of process intensification, continuous manufacturing, hybrid facilities, and digital bioprocessing.

**Advanced-therapy production remains a focus:
** Partnerships are targeting lentiviral-vector manufacturing for emerging in vivo therapies, while new facilities and technology investments aim to expand capacity for cell therapies and other complex biologics.

**Capacity investment comes with trade-offs:
** Companies are expanding plants and capabilities, but industry coverage also flags rising costs, workforce pressures, and geopolitical uncertainty as factors shaping where and how manufacturing capacity is built.